Lightlake Therapeutics, Inc. (LLTP) Targeting Addictions and Related Disorders with Platform of Innovative Intranasal Naloxone Solutions
Lightlake Therapeutics, Inc. (OTCQB: LLTP) is a specialty pharmaceutical company engaged in the development of pharmacological treatments for substance abuse, addiction and eating disorders. In December 2014, the company entered into a global licensing deal with a subsidiary of Adapt Pharma Limited to develop and commercialize Lightlake’s innovative intranasal naloxone opioid overdose reversal treatment, NARCAN® Nasal Spray. As per the terms of this deal, Lightlake could receive potential development and sales milestone payments totaling more than $55 million – including a $2 million milestone payment following FDA approval and a $2.5 million milestone payment following the first commercial sale of…